Stephanie Yao
Plus aucun poste en cours
Profil
Stephanie Yao, formerly the Executive Director of Investor Relations at Kronos Bio, Inc., the Investor Relations Contact at Global Blood Therapeutics, Inc., and the Vice President of Communications & Investor Relations at Graphite Bio, Inc.
Anciens postes connus de Stephanie Yao
| Sociétés | Poste | Fin |
|---|---|---|
| KRONOS BIO, INC. | Investor Relations Contact | - |
| LENZ THERAPEUTICS, INC. | Investor Relations Contact | - |
| GLOBAL BLOOD THERAPEUTICS, INC. | Investor Relations Contact | - |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KRONOS BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
